ClinicalTrials.gg
Active, not recruitingNCT07262229Respir'airBPCOUpdated Jul 13, 2026

Self-management Digital Intervention to Promote Physical Activity in People Living With COPD

An interventional study of Respir'air BPCO in COPD (Chronic Obstructive Pulmonary Disease), Self-management and E-health, sponsored by Institut et Haute Ecole de la Santé la Source. Active, not recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Institut et Haute Ecole de la Santé la Source · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland — 15 open to participants now, 20 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Switzerland.

Enrollment
69th of 77
23 · median 74
Started
2026
with 6 others
No phase
46 of 99
8 open now
Primary completion
2026-11
later than 5 of 19 live
Registered
95th of 99
by date

Among the 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland, this one is the 69th largest by enrollment of the 77 interventional ones that give a count, is one of 7 that started in 2026, is one of 46 with no phase, reaches primary completion later than 5 of the 19 other live ones, and was the 95th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

15 of the 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland, or all of them as a file.
02

Study summary

The goal of this pilot randomized controlled trial is to evaluate the feasibility, acceptability, and preliminary effects of a theory-based self-management digital intervention (Respir'air BPCO) designed to promote physical activity in patients with Chronic Obstructive Pulmonary Disease (COPD) after completion of a pulmonary rehabilitation program.

The main question it aims to answer is:

Is the Respir'air BPCO intervention (mobile app) feasible, acceptable, and preliminarily effective in increasing physical activity, enhancing self-management, improving motivation, and quality of life, while reducing dyspnea severity, exacerbations, and hospitalizations, compared with no additional intervention?

Researchers will compare an experimental group (receiving the Respir'air BPCO intervention + usual care) to a control group (no additional intervention, only usual care)

Participants will:

Be assigned either to the control group, receiving no additional intervention beyond usual care (traditional pulmonologist follow-up), or to the experimental group, receiving access to the Respir'air BPCO mobile app in addition to usual care.

  • Complete baseline assessments immediately after finishing their in-person pulmonary rehabilitation program.
  • Complete follow-up assessments at 3 months and 6 months after the start of the intervention
03

Conditions studied

  • COPD (Chronic Obstructive Pulmonary Disease)
  • Self-management
  • E-health

Keywords

  • self-management
  • COPD
  • eHealth
  • digital intervention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. a GOLD diagnosis stage 1 to 4, classification B or E;
  2. admitted electively at Hospital for PR;
  3. had completed the pulmonary rehabilitation program;
  4. age over 18 years;
  5. ability to provide ;
  6. internet access;
  7. ownership of a smartphone or tablet;
  8. self-assessed perceived ease of use of digital devices.

Exclusion criteria

Exclusion Criteria:

  1. clinical instability confirmed by the team of healthcare professionals;
  2. severe cardiovascular disease confirmed by medical diagnosis;
  3. recent history of neoplasia or disease; other physical activity-limiting clinical condition confirmed by medical diagnosis (e.g. neurological disease);
  4. other respiratory disease as primary diagnosis; e) inability to read, understand or speak French;

f) cognitive impairment diagnosed by the medical team.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • No intervention
    Usual Care

    Traditional pulmonologist follow-up, along with physiotherapy sessions

  • Experimental
    Respir'air BPCO

    Self-management digital intervention (Respir'air BPCO)

    Behavioral: Respir'air BPCO

Interventions

  • BehavioralRespir'air BPCO

    Self-management digital intervention (Respir'air BPCO) grounded in theory (Self-Care Theory of Chronic Illness, Self-Determination Theory of Human Motivation, and the Behavior Change Techniques taxonomy). The mobile application includes educational resources (text, video, images), examples of physical activities (walking, etc), environmental data (air quality), a personal activity log (daily steps), reminders and motivational messages.

06

What researchers measure

Primary outcomes

  1. Trial methodological feasibility indicator - Time required to complete recruitment

    Time frame: T0 - End of face-to-face PR program (Researchers expect to need 3 months to recruit 20 participants.)

  2. Trial methodological feasibility indicator - Consent rate

    Consent rate: proportion of eligible participants who sign the informed consent form

    Time frame: T0: Within 72 hours after completion of the face-to-face PR program

  3. Trial methodological feasibility indicator - Retention rates

    Retention rate: proportion of enrolled participants who remain in the study until the final assessment point

    Time frame: T -1: 1 week before completion of the face-to-face PR program (±72 hours)

  4. Trial methodological feasibility indicator - Acceptance rate of the allocated group

    Acceptance rate will be assessed using administrative study records. It will be defined as the proportion of enrolled participants who agree to participate in the group to which they were allocated (control or intervention) immediately after randomization.

    Time frame: T -1: 1 week before completion of the face-to-face PR program (±72 hours)

  5. Trial methodological feasibility indicator - Proportion of missing data in the completed questionnaires/pedometer

    Time frame: T0: Within 72 hours after completion of the face-to-face PR program T1: 3 months after the start of the intervention (±1 week) T2: 6 months after the start of the intervention (±1 week)

  6. Intervention feasibility indicator - Intervention fidelity

    Exposure rate to all content available within the mobile application

    Time frame: T1: 3 months after the start of the intervention (±1 week) T2: 6 months after the start of the intervention (±1 week)

  7. Intervention feasibility indicators - Number of technical problems auto reported by the patient

    Time frame: T1: 3 months after the start of the intervention (±1 week) T2: 6 months after the start of the intervention (±1 week)

  8. Intervention feasibility indicator - Potential refinements after the completion of the pilot study

    A digital logbook for researchers' use, to record any observations or comments (patients and/or researchers perspectives) regarding the intervention design, content and/or usage, with the aim of informing potential refinements after the completion of the pilot study

    Time frame: From the start of the intervention to study completion, assessed for up to 9 months.

  9. Intervention acceptability indicators - App usage

    Daily App Login Status

    Time frame: T1: 3 months after the start of the intervention (±1 week) T2: 6 months after the start of the intervention (±1 week)

  10. Intervention acceptability indicators - Intervention acceptance

    French-adapted version of the Treatment Acceptance and Preference (TAP) questionnaire.Responses are scored on a five-point Likert scale ranging from 0 ("not at all") to 4 ("extremely"), with higher scores reflecting greater acceptance.

    Time frame: T1: 3 months after the start of the intervention (±1 week) T2: 6 months after the start of the intervention (±1 week)

Secondary outcomes

  1. Preliminary effectiveness measures - Main variable: number of daily steps

    Yamax Power Walker EX-510 pedometer over 5 consecutive days

    Time frame: T0: Within 72 hours after completion of the face-to-face PR program T1: 3 months after the start of the intervention (±1 week) T2: 6 months after the start of the intervention (±1 week)

  2. Preliminary effectiveness measures - secondary variable: Self-management

    Self-Care in Chronic Obstructive Pulmonary Disease Inventory (SC-COPDI). Overall standardized scores ranges for each of the three subscales range from 0 to 100. Higher scores indicate higher levels of self-care in COPD patients.

    Time frame: T0: Within 72 hours after completion of the face-to-face PR program T1: 3 months after the start of the intervention (±1 week) T2: 6 months after the start of the intervention (±1 week)

  3. Preliminary effectiveness measures - secondary variable: Motivational regulation of physical activity

    French-version of the Behavioural Regulation in Exercise Questionnaire-3 (BREQ-3). The score is obtained by averaging responses on a Likert scale ranging from "not at all true" (0) to "very true" (4). Higher scores indicate higher levels of motivation corresponding to the factor being assessed.

    Time frame: T0: Within 72 hours after completion of the face-to-face PR program T1: 3 months after the start of the intervention (±1 week) T2: 6 months after the start of the intervention (±1 week)

  4. Preliminary effectiveness measures - secondary variable: Health-related quality of life

    French version of the disease-specific St George's Respiratory Questionnaire. Each item is assigned a weight based on the level of distress attributed to each symptom or condition described. Overall scores range from 0 (no effect on quality of life) to a maximum score of 100 (maximum perceived suffering). A higher score means a poorer quality of life. French version of the EQ-5D-5L questionnaire. Each dimension is rated according to five levels of severity: from "no problem" (0) to "extreme problem" (4). EQ-5D-5L includes a visual analog scale (VAS) that allows participants to rate their general state of health on a scale from 0 to 100. Higher scores correspond to better health-related quality of life

    Time frame: T0: Within 72 hours after completion of the face-to-face PR program T1: 3 months after the start of the intervention (±1 week) T2: 6 months after the start of the intervention (±1 week)

  5. Preliminary effectiveness measures - secondary variable: severity of dyspnea

    French version of the mMRC Dyspnoea Scale. Uses a scale from 0 to 4. A score of 4 represents the highest severity of the dyspnea

    Time frame: T0: Within 72 hours after completion of the face-to-face PR program T1: 3 months after the start of the intervention (±1 week) T2: 6 months after the start of the intervention (±1 week)

  6. Preliminary effectiveness measures - secondary variable: number of exacerbations

    Self-reported data

    Time frame: T1: 3 months after the start of the intervention (±1 week) T2: 6 months after the start of the intervention (±1 week)

  7. Preliminary effectiveness measures - secondary variable: number of hospitalizations

    Self-reported data

    Time frame: T1: 3 months after the start of the intervention (±1 week) T2: 6 months after the start of the intervention (±1 week)

07

Study locations

1 site
  • Pôle de pneumologie de l'Hôpital de Rolle
    Rolle, Switzerland
08

References and documents

Publications

  • Salgado R, Amiguet M, Costa P, Delmas P, Padilha JM. Self-management digital intervention to promote physical activity in people living with chronic obstructive pulmonary disease: a pilot randomised controlled trial study protocol. BMJ Open. 2026 Jul 24;16(7):e116719. doi: 10.1136/bmjopen-2026-116719. PubMed 42498466 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) underlying the results reported in publications, including demographic characteristics, outcome measures, and study variables necessary to reproduce the analyses, will be made available upon reasonable request to the Principal Investigator. Given the relatively small sample size and the detailed clinical information collected in this single-centre study, full anonymization in the legal sense (i.e., irreversible de-identification with no reasonable means of re-identification) may not be achievable for all variables. A disclosure risk assessment will therefore be conducted once data collection is complete, to determine an appropriate level of data granularity. Depending on the outcome of this assessment, high-risk quasi-identifiers (e.g., precise age, detailed geographic or clinical subgroup information) may be generalized, aggregated, or withheld, and data will be shared through a secure transfer platform.

Supporting information: Study protocol, Analytic code

Time frame: Data and supporting documents will be made available beginning 6 months after publication of the primary study results and will remain available for 5 years thereafter. Recipients will be required to securely destroy all shared at the end of the approved project.

Access criteria: Access will be granted to qualified researchers whose proposed use of the data has been approved following review by the Principal Investigator (or, in the event of the PI's unavailability, a designated institutional data steward) and is consistent with the participants' informed consent, the original ethical approval, and applicable Swiss and, where relevant, other data protection regulations. Requests must include a methodologically sound research proposal and will be evaluated for consistency with the scope of participant consent. Data will be shared as de-identified datasets after execution of a Data Sharing Agreement (DSA). The DSA will require the recipient to: (a) not attempt to re-identify participants; (b) not redistribute the data to third parties; (c) store and process the data under specified security standards; and (d) destroy the data at the end of the agreed period.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Nov 2026, 10 months after the start.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 10 months is below that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 3, 2025
StartActual
Jan 22, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07262229
Lead sponsor
Institut et Haute Ecole de la Santé la Source
Responsible party
Ricardo Salgado (Senior Lecturer UAS, Institut et Haute Ecole de la Santé la Source) — Principal investigator
First posted
Dec 3, 2025
Start date
Jan 22, 2026
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Jul 13, 2026

Study contacts

Ricardo Salgado, MSc
principal investigator · Institut et Haute Ecole de la Santé la Source

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion